Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | CASP7 | P55210 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.52 |
| ▸ | GRM5 | P41594 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5858951 | 0.88 | MAOA (0.61) | CASP1CASP7HSD17B10HSD17B1GRM5 | |
| SCHEMBL7974509 | 0.85 | CASP1 (0.44) | CASP1CASP7HSD17B10HSD17B1GRM5 | |
| SCHEMBL8871212 | 0.83 | PBRM1 (0.59) | CASP1CASP7HSD17B10HSD17B1GRM5 | |
| SCHEMBL1045951 | 0.78 | CASP1 (0.59) | CASP1CASP7HSD17B10HSD17B1GRM5 | |
| SCHEMBL28655414 | 0.77 | HSD17B1 (0.78) | CASP1CASP7HSD17B10HSD17B1GRM5 | |
| SCHEMBL5538267 | 0.76 | CASP1 (0.61) | CASP1CASP7HSD17B10HSD17B1GRM5 | |
| SCHEMBL883774 | 0.74 | CASP1 (0.59) | CASP1CASP7HSD17B10HSD17B1GRM5 | |
| SCHEMBL192610 | 0.74 | CASP1 (0.59) | CASP1CASP7HSD17B10HSD17B1GRM5 | |
| SCHEMBL16082766 | 0.74 | CASP1 (0.59) | CASP1CASP7HSD17B10HSD17B1GRM5 | |
| SCHEMBL434358 | 0.74 | CASP1 (1.00) | CASP1CASP7HSD17B10HSD17B1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016044770-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-7220734-B2 | 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as Edg receptor agonists | MERCK & CO., INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-5607928-A | Carbapenem derivatives containing a bicyclic ketone substituent and their use as anti-infectives | ZENECA LIMITED (GB) | 1997-03-04 | — | — | US | disclosed |
| EP-0695753-A1 | Carbapenem derivatives containing a bicyclic substituent, process for their preparation, and their use | ZENECA LIMITED (GB) | 1996-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | CASP1 3636/4885CASP7 2506/4885HSD17B10 508/4885 |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, KAT2A | CASP1 3478/4885CASP7 2621/4885HSD17B10 417/4885 |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | CASP1 3636/4885CASP7 2506/4885HSD17B10 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.